US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Philochem to license worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer to RayzeBio: Otelfingen, Switzerland Thur ...

In accordance with the agreement, Philochem will get $350 million up front and could get up to $1 billion in milestone ...

Bristol MyersBMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis ...

Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new ...

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal in the space of a week.

The larger of the two deals was made by BMS, with a deal sealed right at the end of 2023 to acquire RayzeBio for $4.1 billion. RayzeBio’s pipeline includes multiple RPT prospects, including its ...

Bristol Myers' Sotyktu, a TYK2 inhibitor already approved for psoriasis, scored a win in a Phase III trial for psoriatic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...